Sanofi (SNYNF)

OTCMKTS · Delayed Price · Currency is USD
98.65
+3.90 (4.12%)
Dec 20, 2024, 3:00 PM EST
2.79%
Market Cap 119.62B
Revenue (ttm) 54.03B
Net Income (ttm) 5.03B
Shares Out n/a
EPS (ttm) 4.00
PE Ratio 23.80
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open 98.65
Previous Close 94.75
Day's Range 98.65 - 98.65
52-Week Range 90.45 - 119.65
Beta 0.42
Analysts n/a
Price Target n/a
Earnings Date Jan 30, 2025

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric ... [Read more]

Sector Healthcare
Founded 1994
Employees 86,088
Stock Exchange OTCMKTS
Ticker Symbol SNYNF
Full Company Profile

Financial Performance

In 2023, Sanofi's revenue was 46.03 billion, an increase of 1.42% compared to the previous year's 45.39 billion. Earnings were 5.40 billion, a decrease of -35.49%.

Financial numbers in EUR Financial Statements

News

Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

1 day ago - GlobeNewsWire

Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio? Teva Pharmaceutical Industries Limited (NYSE: TEVA) stock escalated 33.88% after the company and Sano...

1 day ago - Benzinga

Sanofi to buy China rights to Cytokinetics lead asset

Cytokinetics (CYTK) stock is in focus as Sanofi (SNY) agrees to buy exclusive rights to its lead drug aficamten in Greater China. Read more here.

3 days ago - Seeking Alpha

Cytokinetics Inc (CYTK) Announces Sanofi's Acquisition of Aficamten Rights in Greater China

Cytokinetics Inc (CYTK) Announces Sanofi's Acquisition of Aficamten Rights in Greater China

4 days ago - GuruFocus

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024. Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025, replac...

4 days ago - GlobeNewsWire

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases

Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets. ... Full story available on Benzinga.co...

5 days ago - Benzinga

Sanofi and Teva Achieve Milestone in Ulcerative Colitis Treatment Study

Sanofi and Teva Achieve Milestone in Ulcerative Colitis Treatment Study

5 days ago - GuruFocus

Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's

Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn's disease.

6 days ago - Investopedia

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.

6 days ago - The Wall Street Journal

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.

6 days ago - WSJ

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

Teva and Sanofi's Phase 2b RELIEVE ... Full story available on Benzinga.com

6 days ago - Benzinga

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

On Tuesday, Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).

6 days ago - Benzinga

Sanofi's 340B Credit Proposal Draws Federal Warning For Statutory Violation

The Health Resources and Services Administration (HRSA) has warned Sanofi SA (NASDAQ: SNY) about its proposed credit model for certain outpatient drugs under the 340B program. HRSA asserts that the c...

6 days ago - Benzinga

BrightInsight Expands Global Digital Partnership with Sanofi to Build Drug Companion Apps for its Major Specialty Therapies

BrightInsight announced an expanded global digital partnership with Sanofi to build branded patient apps to drive adoption, adherence, and persistence.

6 days ago - GlobeNewsWire

Teva, Sanofi gain after mid-stage trial win for IBD therapy

Teva (TEVA) stock and Sanofi (SNY) stock jump after a mid-stage trial win for an experimental antibody therapy targeting inflammatory bowel diseases. Read more here.

6 days ago - Seeking Alpha

Teva, Sanofi say drug to treat IBD met primary targets

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals.

6 days ago - Reuters

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most co...

6 days ago - Benzinga

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease

Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the h...

6 days ago - Benzinga

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most co...

6 days ago - GlobeNewsWire

Press Release: Availability of the Q4 2024 Aide-mémoire

Availability of the Q4 2024 Aide-mémoire Paris, France – December 17, 2024 . Sanofi announced today that its Q4 2024 Aide-mémoire is available on the "Investors" page of the company's website: Fourth ...

7 days ago - Benzinga

Pharmaceutical leaders convene in Paris to unveil vaccine strategies

Pfizer, Sanofi, Moderna, GSK and Novavax confirmed their attendance to Euractiv. The post Pharmaceutical leaders convene in Paris to unveil vaccine strategies appeared first on Euractiv .

7 days ago - EURACTIV.com

Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with non-r...

11 days ago - GlobeNewsWire

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who prepares to leave early next year.

11 days ago - Reuters

Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US

Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US First non-mRNA combination vaccine candidates that include two already licensed vac...

13 days ago - GlobeNewsWire

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained MR...

14 days ago - GlobeNewsWire